Recent performance snapshot Biogen (BIIB) shares closed at US$171.59, with performance mixed across recent periods. The stock shows a 1 day return of about a 1% decline, a 4.4% gain over the past week ...

Biogen's CEO says the company's late-stage pipeline is in good shape, but the drugmaker is still hunting for deals to build ...

During the first day of the 44 th Annual JP Morgan Healthcare Conference in San Francisco, a clear narrative emerged. With ...

Eisai and Biogen’s Supplemental Biologics License Application (sBLA) for Leqembi (lecanemab) subcutaneous autoinjector (SC-AI) has been accepted by the US FDA under Priority Review to treat early ...

Three years after the accelerated approval of its anti-amyloid Alzheimer’s therapy, Biogen—neck and neck in the market with ...

If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease FDA acti ...

Biogen Inc.’s new at-home Alzheimer’s drug will give the company an edge over rival Eli Lilly Co.’s competing therapy, its ...

Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all ...

Proximity Health Solutions, in collaboration with Biogen, announces that Better Together: Sharing Our Lupus Stories has been selected as one of the four finalists for the prestigious 2026 SCOPE ...

Approval is supported by data from the DEVOTE study which showed the benefit of the SPINRAZA 50 mg and 28 mg regimen in both treatment-naïve and previously-treated nusinersen patients with SMA1Biogen ...

Biogen Inc. (NASDAQ:BIIB) is one of the best performing pharma stocks in 2025. Biogen Inc. (NASDAQ:BIIB) received several rating updates on January 8. Truist lifted the price target on the stock to ...

US biotech Biogen (Nasdaq: BIIB) said the European Commission on January 12, 2026 granted marketing authorization for a ...